Coherus BioSciences, Inc. (CHRS:NASDAQ) closed at $1.07 on October 13, 2026, up 3.88% on the day. The stock trades 59.1% below its 52-week high of $2.62 and 9.9% above its 52-week low of $0.974. Over the past year, it lost 37.1%. Coherus BioSciences, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| 0.00% | -25.17% | -23.02% | -45.96% | -37.06% |
In 252 trading sessions since October 13, 2025, CHRS closed higher on 114 days (45%). Its best day was January 23, 2026 (+29.56%) and its worst was February 13, 2026 (-19.90%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 2 times.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of...
Find more stocks like CHRS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.